ES2073678T3 - Formulaciones radiofarmaceuticas, su metodo de administracion y procedimiento de preparacion. - Google Patents

Formulaciones radiofarmaceuticas, su metodo de administracion y procedimiento de preparacion.

Info

Publication number
ES2073678T3
ES2073678T3 ES91305485T ES91305485T ES2073678T3 ES 2073678 T3 ES2073678 T3 ES 2073678T3 ES 91305485 T ES91305485 T ES 91305485T ES 91305485 T ES91305485 T ES 91305485T ES 2073678 T3 ES2073678 T3 ES 2073678T3
Authority
ES
Spain
Prior art keywords
radiopharmaceutical formulations
administration
preparation procedure
ligand
frozen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91305485T
Other languages
English (en)
Inventor
Jaime Simon
Joseph R Garlich
R Keith Frank
Kenneth Mcmillan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Chemical Co
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Application granted granted Critical
Publication of ES2073678T3 publication Critical patent/ES2073678T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

FORMULACIONES RADIOFARMACEUTICAS PARA COMPLEJOS COMPRENDIENDO AL MENOS UN RADIONUCLIDO COMPLEJO CON UN LIGADOR, O SUS SALES FISIOLOGICAMENTE ACEPTABLES, ESPECIALMENTE ACIDO SAMARIM-ETILENEDIAMINE-TETRAMETILENO-FOSFONICO, QUE OPCIONALMENTE CONTIENE UN ION DE METAL DIVALENTE POR EJ., CALCIO Y ES CONGELADO DERRETIDO, Y DESPUES ADMINISTRADO POR INYECCION. ALTERNATIVAMENTE, LAS FORMULACIONES RADIOFARMACEUTICAS DEBEN CONTENER EL METAL DIVALENTE Y SON CONGELADAS SOLAMENTE SI EL PERIODO ANTES DE SU ADMINISTRACION ES SUFICIENTEMENTE LARGO PARA CONCERNIR A LA RADIOLISIS DEL LIGADOR.
ES91305485T 1990-06-18 1991-06-18 Formulaciones radiofarmaceuticas, su metodo de administracion y procedimiento de preparacion. Expired - Lifetime ES2073678T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53887190A 1990-06-18 1990-06-18

Publications (1)

Publication Number Publication Date
ES2073678T3 true ES2073678T3 (es) 1995-08-16

Family

ID=24148781

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91305485T Expired - Lifetime ES2073678T3 (es) 1990-06-18 1991-06-18 Formulaciones radiofarmaceuticas, su metodo de administracion y procedimiento de preparacion.

Country Status (32)

Country Link
US (1) US5762907A (es)
EP (1) EP0462787B1 (es)
JP (2) JP3636728B2 (es)
KR (1) KR100219964B1 (es)
CN (1) CN1033143C (es)
AT (1) ATE123955T1 (es)
AU (2) AU651112B2 (es)
BR (2) BR9102579A (es)
CA (1) CA2044812C (es)
CS (1) CS184291A3 (es)
CY (1) CY1891A (es)
DE (1) DE69110554T2 (es)
DK (1) DK0462787T3 (es)
EG (1) EG19862A (es)
ES (1) ES2073678T3 (es)
FI (1) FI101044B (es)
GR (1) GR3017430T3 (es)
HK (1) HK80496A (es)
HU (1) HU226897B1 (es)
IE (1) IE71023B1 (es)
IL (1) IL98536A (es)
IS (1) IS1704B (es)
MC (1) MC2260A1 (es)
NO (1) NO302510B1 (es)
NZ (1) NZ238547A (es)
PH (1) PH30975A (es)
PL (1) PL165699B1 (es)
PT (1) PT97996B (es)
RU (1) RU2095085C1 (es)
SA (1) SA92120343B1 (es)
SK (1) SK279598B6 (es)
ZA (1) ZA914615B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5410043A (en) * 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
US5320829A (en) * 1991-12-10 1994-06-14 The Dow Chemical Company Oral compositions for inhibiting plaque formation
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5405601A (en) * 1993-07-02 1995-04-11 Mallinckrodt Medical Inc. Functionalized tripodal ligands for imaging applications
CN1065769C (zh) * 1997-07-03 2001-05-16 中国原子能科学研究院 一种放射性药物制剂的制备方法
CN1092962C (zh) * 1998-01-26 2002-10-23 贾伟 一种减轻骨及骨关节疾病疼痛的药物
EP1191948A2 (en) * 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
EP1390081A2 (en) * 2001-01-08 2004-02-25 Neorx Corporation Therapeutic and diagnostic compounds, compositions, and methods
US6567492B2 (en) 2001-06-11 2003-05-20 Eastern Isotopes, Inc. Process and apparatus for production of F-18 fluoride
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
ATE473019T1 (de) 2002-11-05 2010-07-15 Ion Beam Applic Sa Stabilisierung von wässerigen zusammensetzungen von 18f-markiertem 2-fluoro-2-deoxy-d-glukose mit ethanol
US9636404B2 (en) 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
PL3054996T3 (pl) 2013-10-07 2023-09-18 Igl Pharma, Inc. Sposób wytwarzania wysoce czystych środków do leczenia kości
RU2719399C2 (ru) * 2014-12-04 2020-04-17 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ удаления ацетальдегида из радиоактивных фармацевтических препаратов
RU2593017C1 (ru) * 2015-04-23 2016-07-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения радиофармацевтического препарата "астат-211"
WO2016187514A1 (en) * 2015-05-21 2016-11-24 Actinium Pharmaceueuticals, Inc. Infusion administration of conjugated monoclonal antibodies
US11369700B2 (en) * 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
EP3302496B1 (en) * 2015-05-25 2021-01-06 IGL Pharma, Inc. Dotmp kit formulations for radioisotopes
RU2757258C1 (ru) * 2020-09-28 2021-10-12 федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский ядерный университет "МИФИ" (НИЯУ МИФИ) Способ получения радиофармацевтического препарата с галлием-68 для визуализации метастазов скелета методом пэт

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018883A (en) * 1975-03-10 1977-04-19 Nichols Institute For Endocrinology Thyroxine (T4) radioimmunoassay
CA1050425A (en) * 1975-06-26 1979-03-13 Mallinckrodt Radioimmunoassay methods for the determination of l-triiodothyronine and thyroxine
US4301140A (en) * 1979-12-14 1981-11-17 G. D. Searle & Co. Radiopharmaceutical method for monitoring kidneys
US4341755A (en) * 1980-07-15 1982-07-27 Immuno Nuclear Corporation Parathyroid radioimmunoassay
US4457602A (en) * 1981-04-20 1984-07-03 Olympus Optical Company Ltd. Multiple light emission control system utilizing electronic flashes
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
DE3583257D1 (de) * 1984-06-04 1991-07-25 Dow Chemical Co Organische aminphosphonsaeurekomplexe fuer die behandlung von verkalkenden tumoren.
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
GB8510726D0 (en) * 1985-04-26 1985-06-26 Amersham Int Plc Stabilised radio-labelled compounds
US4752464A (en) * 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
NZ222304A (en) * 1987-05-18 1990-10-26 Dow Chemical Co Suppression of bone marrow using samarium-153, gadolinium-159 or holmium-166 complexes
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
WO1989000052A1 (en) * 1987-06-30 1989-01-12 Mallinckrodt, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonants imaging agents and x-ray contrast agents
US4937333A (en) * 1989-08-04 1990-06-26 The Dow Chemical Company Method for purifying aminomethylenephosphonic acids for pharmaceutical use
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes

Also Published As

Publication number Publication date
NO912345L (no) 1991-12-19
BR1101169A (pt) 2000-08-08
CY1891A (en) 1996-08-30
KR920000334A (ko) 1992-01-29
FI912933A (fi) 1991-12-19
BR9102579A (pt) 1992-01-21
JP3636728B2 (ja) 2005-04-06
HUT57994A (en) 1992-01-28
RU2095085C1 (ru) 1997-11-10
IE71023B1 (en) 1997-01-15
EG19862A (en) 1996-06-30
FI912933A0 (fi) 1991-06-17
HK80496A (en) 1996-05-17
PH30975A (en) 1997-12-23
PT97996B (pt) 1998-11-30
NO302510B1 (no) 1998-03-16
NO912345D0 (no) 1991-06-17
AU651112B2 (en) 1994-07-14
AU6455994A (en) 1994-08-04
EP0462787A1 (en) 1991-12-27
PL290717A1 (en) 1992-02-24
IE912057A1 (en) 1991-12-18
US5762907A (en) 1998-06-09
SK279598B6 (sk) 1999-01-11
IS3717A7 (is) 1991-12-19
AU665911B2 (en) 1996-01-18
AU7847091A (en) 1991-12-19
DE69110554D1 (de) 1995-07-27
HU226897B1 (en) 2010-01-28
CN1033143C (zh) 1996-10-30
IL98536A0 (en) 1992-07-15
CA2044812C (en) 2002-12-31
HU912011D0 (en) 1991-12-30
GR3017430T3 (en) 1995-12-31
JP2002114712A (ja) 2002-04-16
JPH04230224A (ja) 1992-08-19
KR100219964B1 (ko) 1999-09-01
EP0462787B1 (en) 1995-06-21
NZ238547A (en) 1994-05-26
SA92120343B1 (ar) 2004-01-25
DK0462787T3 (da) 1995-10-30
ZA914615B (en) 1993-02-24
CS184291A3 (en) 1992-02-19
PT97996A (pt) 1992-03-31
IL98536A (en) 1996-10-31
PL165699B1 (pl) 1995-01-31
ATE123955T1 (de) 1995-07-15
IS1704B (is) 1998-12-10
DE69110554T2 (de) 1995-12-14
CN1063615A (zh) 1992-08-19
MC2260A1 (fr) 1993-04-26
CA2044812A1 (en) 1991-12-19
FI101044B (fi) 1998-04-15

Similar Documents

Publication Publication Date Title
ES2073678T3 (es) Formulaciones radiofarmaceuticas, su metodo de administracion y procedimiento de preparacion.
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
GB1489330A (en) Stable diagnostic reagents
DK280789D0 (da) Komplekser af beta-cyclodextrin med salte af ibuprofen, fremgangsmaade til fremstilling af saadanne komplekser og farmaceutiske midler indeholdende disse
DE3267039D1 (en) Stable s-adenosylmethionine salts, the process for their preparation and therapeutic compositions which contain them as active principle
DE68908125D1 (de) Knochenmark unterdrueckende medikamente.
WO1992000759A3 (en) Stabilized therapeutic radiopharmaceutical complexes
SE9002500D0 (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
SE7706126L (sv) Radioaktivt preparat
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
NO924647L (no) Krystallinske fumarsyresalter av 9,9-alkylen-3,7-diazabicyklononanforbindelser, og legemidler inneholdende disse
ATE23800T1 (de) Roentgen-sichtbarmachungsmittel.
Dubois et al. A scintiscan study of renal form and function using Technetium-labeled ferrous ascorbate
JPS5573608A (en) Stable diagnosing drug for radioactive technetium labeling

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 462787

Country of ref document: ES